Hanmi’s Amosartan First To Benefit From Korean Linkage System
This article was originally published in PharmAsia News
Executive Summary
Hanmi Pharm's Amosartan combination drug has been selected as the first product whose generic versions will be given nine months of marketing exclusivity under Korea’s new patent-approval linkage system.